67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

NCT04023331 PHASE1, PHASE2 TERMINATED

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Details

Lead sponsor	Clarity Pharmaceuticals Ltd
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	21
Start date	Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neuroblastoma
• Relapsed Neuroblastoma
• Refractory Neuroblastoma

Interventions

• 67Cu-SARTATE
• 64Cu-SARTATE

Countries

United States